Pharmaceutical group ยท United States
Incyte
A group of 8 companies with 51 medicines in 7 countries.
Group structure
8 companies in 5 countries
Loading your pageโฆ
Loading your pageโฆ
Pharmaceutical group ยท United States
A group of 8 companies with 51 medicines in 7 countries.
8 companies in 5 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 51
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ICLUSIGCompressa rivestita con film | Ponatinib | Italy | Authorised | |
| Iclusig | Ponatinib | EU (EMA) | Authorised | 2013 |
| ICLUSIG 15 MG COMPRIMIDOS RECUBIERTOS CON PELICULA15 mg ยท Comprimido recubierto con pelรญcula | Ponatinib | Spain | Marketed | 2016 |
| Iclusig 15 mg, filmomhulde tabletFilmomhulde tablet | Ponatinib | Netherlands | Authorised | 2013 |
| ICLUSIG 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULA30 mg ยท Comprimido recubierto con pelรญcula | Ponatinib | Spain | Marketed | 2016 |
| Iclusig 30 mg, filmomhulde tabletFilmomhulde tablet | Ponatinib | Netherlands | Authorised | 2016 |
| ICLUSIG 45 MG COMPRIMIDOS RECUBIERTOS CON PELICULA45 mg ยท Comprimido | Ponatinib | Spain | Marketed | 2013 |
| Iclusig 45 mg, filmomhulde tabletFilmomhulde tablet | Ponatinib | Netherlands | Authorised | 2013 |
| Iclusig 5 mg harde capsulesCapsule, hard | Ponatinib | Netherlands | Authorised | 2013 |
| JAKAFI10mg base | 15mg base | 20mg base | 25mg base | 5mg base ยท Tablet | Ruxolitinib | United States | Marketed | 2011 |
| JAKAFI XR11mg base | 22mg base | 33mg base | 44mg base | 55mg base ยท Tablet, extended release | Ruxolitinib | United States | Marketed | 2026 |
| MINJUVIPolvere per concentrato per soluzione per infusione | Tafasitamab | Italy | Authorised | |
| Minjuvi | Tafasitamab | EU (EMA) | Authorised | 2021 |
| MINJUVI200 mg / vial ยท Powder For Solution | Tafasitamab | Canada | Marketed | 2021 |
| Minjuvi 200 mg poeder voor concentraat voor oplossing voor infusiePoeder voor concentraat voor oplossing voor infusie | Tafasitamab | Netherlands | Authorised | 2021 |
| MINJUVI 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION200 mg ยท Polvo para concentrado para soluciรณn para perfusiรณn | Tafasitamab | Spain | Marketed | 2021 |
| Niktimvo22mg/2.2ml (10mg/ml) ยท Injection | Axatilimab | United States | Marketed | 2026 |
| Niktimvo9mg/0.18ml (50mg/ml) ยท Injection | Axatilimab | United States | Marketed | 2025 |
| NIKTIMVO50 mg/ml ยท Injectable | Axatilimab | United States | Marketed | 2024 |
| Niktimvo22mg/0.44ml (50mg/ml) ยท Injection | Axatilimab | United States | Marketed | 2025 |
| Niktimvo9mg/0.9ml (10mg/ml) ยท Injection | Axatilimab | United States | Marketed | 2026 |
| OPZELURA1.5% base ยท Cream | Ruxolitinib | United States | Marketed | 2021 |
| OPZELURACrema | Ruxolitinib | Italy | Authorised | |
| OPZELURA1.5 % / w/w ยท Cream | Ruxolitinib | Canada | Marketed | 2024 |
| Opzelura | Ruxolitinib | EU (EMA) | Authorised | 2023 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Netherlands | 10 | 10 | 0 | CompaniesAll medicines |
| United States | 10 | 10 | 0 | CompaniesAll medicines |
| Spain | 9 | 9 | 0 | CompaniesAll medicines |
| European Union (EMA) | 7 | 5 | 2 | CompaniesAll medicines |
| Canada | 6 | 6 | 0 | CompaniesAll medicines |
| Italy | 5 | 5 | 0 | CompaniesAll medicines |
| Romania | 4 | 0 | 4 | CompaniesAll medicines |
Also in the registers of France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.
Ranked by their number of medicines.